QuantLogix ← RMD scorecard
📅 RMD Earnings Preview
ResMed Inc.
Next report (est.)
August 22, 2026
Countdown
70 days
EPS growth YoY
+10.5%
Revenue growth YoY
+10.8%
Implied vs actual — last 8 reports
ReportOptions impliedActual moveMarket was
May 1, 2026 ±2.4% -4.1% under-priced
January 30, 2026 ±1.8% +0.3% over-priced
October 31, 2025 ±2.3% -2.1% over-priced
April 24, 2025 ±3.4% +10.1% under-priced
January 31, 2025 ±2.9% -8.3% under-priced
October 25, 2024 ±1.9% +7.1% under-priced
April 26, 2024 ±2.0% +18.9% under-priced
January 25, 2024 ±2.8% +8.5% under-priced
Across these reports, options implied an average ±2.4% move vs an actual average of 7.4% — the stock stayed inside the implied band 25% of the time.
Fundamentals into the print
QuarterEPS (dil.)RevenueNet income
Q3 FY2026 $2.74 $1.4B $399M
Q2 FY2026 $2.68 $1.4B $393M
Q1 FY2026 $2.37 $1.3B $349M
Q4 FY2025 $2.58 $1.3B $380M
Live 5-factor engine read: Buy · 54/100 Full scorecard →
Get alerted before every RMD report — free Full live analysis
🤖 Pro runs a 10-agent AI debate on RMD before the print — 5 analysts, bull vs bear, a risk read, and a trader's verdict. See Pro →

ResMed Inc. (RMD) reports in 70 days, with the next report estimated for August 22, 2026. Across the last 8 reports, options priced an average ±2.4% earnings move while the stock actually moved 7.4% on average — the market has tended to under-price RMD's earnings risk. Fundamentals into the print: EPS up 10.5% year-over-year, revenue up 10.8%. QuantLogix's live 5-factor engine currently reads RMD as a buy at 54/100.

Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →